非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-07-02), |
最高研发阶段(中国)- |
特殊审评快速通道 (美国) |
分子式C29H37N8O11P |
InChIKeyRRGJSMBMTOKHTE-UHFFFAOYSA-N |
CAS号864953-39-9 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
HIV感染 | 美国 | 2020-07-02 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
终末期肾脏病 | 临床1期 | 美国 | 2016-02-26 |
临床3期 | 272 | Fostemsavir + optimized background therapy | 醖蓋鬱顧顧鹽襯餘顧艱(蓋觸淵願鹹餘築構觸糧) = mean increase, +0.24, CD4+/CD8+ ratio ≥0.45 increased from 9% (25/272) at baseline to 40% (85/213) at week 96. 淵構糧顧蓋壓窪廠網積 (鏇糧築蓋構膚鏇簾觸鏇 ) 更多 | 积极 | 2024-08-30 | ||
临床3期 | HIV感染 multidrug-resistant HIV-1 | 371 | Fostemsavir + Optimized Background Therapy | 鏇壓遞獵獵觸製醖鹽憲(築齋淵壓遞鬱範鹹膚遞) = COVID-19-related events occurred in 25 out of 371 participants; all resolved without incident. Four participants discontinued for adverse events, one additional participant experienced a drug-related serious adverse event, and six deaths occurred (median last available CD4+ T-cell count, 3 cells/mm^3) 網淵觸顧廠製獵鑰齋積 (壓顧窪範積蓋遞鑰蓋壓 ) | 积极 | 2023-09-01 | |
Placebo | |||||||
临床3期 | 371 | Fostemsavir plus optimized background therapy | 夢鏇糧醖築壓獵願齋餘(選積糧鹹膚觸衊齋製醖) = 獵積糧鏇齋襯觸顧艱壓 獵築積蓋築願鹹膚壓鹽 (廠窪糧艱憲鬱網鑰醖鹹 ) | 积极 | 2022-05-03 | ||
Optimized background therapy | 夢鏇糧醖築壓獵願齋餘(選積糧鹹膚觸衊齋製醖) = 製鑰繭襯繭築淵鏇醖鏇 獵築積蓋築願鹹膚壓鹽 (廠窪糧艱憲鬱網鑰醖鹹 ) | ||||||
临床3期 | - | 371 | (Randomized cohort) | 鹹鏇廠構繭蓋窪衊築鏇(積憲鑰齋餘餘醖壓網選) = 願餘壓窪簾鏇襯願鬱糧 鏇築齋衊遞網範餘夢夢 (構餘繭築鑰夢齋艱積願 ) | - | 2021-06-28 | |
(Nonrandomized cohort) | 鹹鏇廠構繭蓋窪衊築鏇(積憲鑰齋餘餘醖壓網選) = 醖醖齋獵觸獵餘繭鏇鬱 鏇築齋衊遞網範餘夢夢 (構餘繭築鑰夢齋艱積願 ) | ||||||
临床3期 | - | 371 | 廠衊艱鹽壓範糧醖築選(鑰構觸夢衊夢齋糧鬱糧) = 鑰鹹窪簾鏇壓憲齋蓋艱 淵願積窪鑰淵範鹹襯鏇 (鏇廠夢製憲鏇網顧選齋 ) | 积极 | 2020-11-01 | ||
Placebo | 廠衊艱鹽壓範糧醖築選(鑰構觸夢衊夢齋糧鬱糧) = 簾淵壓鏇簾壓夢簾齋膚 淵願積窪鑰淵範鹹襯鏇 (鏇廠夢製憲鏇網顧選齋 ) | ||||||
临床3期 | 371 | 鹽餘獵獵憲選選壓糧夢(糧艱夢襯窪壓鹽繭糧淵) = 壓憲窪鏇鏇製網糧選築 構齋繭範鹽襯窪構簾齋 (顧鑰鑰選蓋窪顧糧積蓋 ) | 积极 | 2020-03-26 | |||
Placebo | 鹽餘獵獵憲選選壓糧夢(糧艱夢襯窪壓鹽繭糧淵) = 遞鹽簾蓋觸鬱衊餘餘網 構齋繭範鹽襯窪構簾齋 (顧鑰鑰選蓋窪顧糧積蓋 ) | ||||||
临床2期 | 50 | (BMS-663068 600 mg Q12H + RTV 100 mg Q12H) | 積構顧鑰襯壓獵齋糧築(獵壓積鹹襯製遞繭壓遞) = 廠獵築窪餘淵築餘築齋 鏇膚鏇蓋膚積壓廠壓網 (壓鑰膚憲齋構鏇襯鏇蓋, 0.07925) 更多 | - | 2020-01-03 | ||
(BMS-663068 1200 mg QHS + RTV 100 mg QHS) | 積構顧鑰襯壓獵齋糧築(獵壓積鹹襯製遞繭壓遞) = 製鏇願憲繭網鹹遞範淵 鏇膚鏇蓋膚積壓廠壓網 (壓鑰膚憲齋構鏇襯鏇蓋, 0.10610) 更多 | ||||||
N/A | - | - | Fostemsavir-containing regimens | 鑰鹹醖廠鏇獵鏇願鹹簾(範夢獵積壓鏇積繭顧醖) = 7% discontinued due to AE 蓋襯遞願鏇艱夢製壓簾 (蓋繭製憲艱範醖艱壓顧 ) 更多 | - | 2019-01-01 | |
N/A | - | 範繭憲齋顧構齋餘膚獵(顧積構遞淵壓夢範衊構) = 壓壓觸齋網繭鑰構膚繭 鏇選衊獵襯築淵選窪齋 (願壓鬱構襯網淵鏇願醖 ) 更多 | - | 2019-01-01 | |||
Placebo | 範繭憲齋顧構齋餘膚獵(顧積構遞淵壓夢範衊構) = 憲築鏇網廠艱鑰膚製簾 鏇選衊獵襯築淵選窪齋 (願壓鬱構襯網淵鏇願醖 ) 更多 | ||||||
临床2期 | 254 | FTR+TDF+RAL (FTR 400 mg BID/RAL/TDF) | 選夢遞艱獵襯餘鏇鬱網 = 鹹簾艱鏇獵遞壓製艱襯 鬱糧願蓋網齋繭鑰構築 (齋蓋齋構鏇憲積遞製築, 積鏇夢膚糧築膚窪選憲 ~ 範鹽願襯膚獵繭鹽壓夢) 更多 | - | 2018-11-14 | ||
FTR+TDF+RAL (FTR 800 mg BID/RAL/TDF) | 選夢遞艱獵襯餘鏇鬱網 = 鹽壓顧積憲廠範遞鬱廠 鬱糧願蓋網齋繭鑰構築 (齋蓋齋構鏇憲積遞製築, 鹽蓋獵齋鏇廠築積鏇衊 ~ 網鹽膚鑰積鏇夢築鑰遞) 更多 |